Non-Hallucinogenic Psychedelic Compound

Enveric Biosciences (NASDAQ:ENVB), a biotechnology company specializing in neuroplastogenic small-molecule therapeutics, revealed positive data from preclinical safety and pharmacology studies of its lead drug candidate, EB-003. The Massachusetts-based company announced that the results show the...

Australia biotech startup Psylo has inked a sponsored research agreement with global Japanese pharmaceutical company Daiichi Sankyo (OTCMKTS: DSNKY) toward advancing antidepressant psychiatric medicines. See also: Building Australia's Psychedelics Industry: A New Joint Venture And Why...

Clinical-stage biotech company Delix Therapeutics announced the initial cohort of its first-in-human Phase 1 trial assessing the safety and efficacy of a new non-hallucinogenic, MDMA and 5-MeO-DMT inspired psychoplastogen has successfully been dosed. Taking place in the Netherlands-based CHRD with...

Psychedelics biotech BetterLife Pharma (OTCQB: BETRF) announced its non-hallucinogenic LSD derivative, BETR-001, is progressing through IND-enabling studies  toward expected clinical studies targeting Major Depressive Disorder (MDD.)  The 2-bromo-LSD molecule’s preclinical...

In response to the question of how psychedelics can prove effective in treating mental health conditions like depression, an international neuroscience team seems to have found a new answer. Published in the Nature Neuroscience journal, results from the preclinical research show that LSD...

Along with a growing scientific corpus supporting the therapeutic potential of psychedelics, several states and most noticeably Massachusetts are seeing the decriminalization of natural substances via local measures.  In reply to what is known to date of psilocybin mushrooms...

Next-gen therapeutics developer Psilera Inc. has achieved a preclinical milestone by having all its first cohort of drug candidates, designed and synthesized in-house, show no hallucinogenic effects in animals. The group includes six patent-pending compounds with novel structural features...

The next-generation psychedelics R&D business is up and running, as BetterLife Pharma Inc. (OTCQB: BETRF)’s lead drug candidate LSD analog BETR-001 has shown positive results in a study assessing it as a potential treatment for mood disorders.  In preclinical and IND-enabling...

BetterLife Pharma (OTCQB: BETRF), a non-hallucinogenic psychedelics biotech company, has contracted Bloom Burton Securities Inc. for strategic advisory services. “Canada’s leading healthcare investment banking firm” holds “extensive understanding” of the overall...

Clinical-stage psychedelics biopharma company Ceruvia Lifesciences has dosed the first participant in its Phase 1 trial on NYPRG-101, aka BOL-148, an LSD non-hallucinogenic analog with a clinical and experimental administration history that dates back to the 1950s. "Having invested...

The University of Wisconsin-Madison Transdisciplinary Center for Research in Psychoactive Substances (TCRPS) was created to foster education and research on the field of medical applications of psychedelics, and one of them is specifically studying if remembering the psychedelic-induced...

In parallel with working towards discovering and advancing therapeutic psychedelics, biopharma companies are continuously protecting their findings. The emerging biotech BetterLife Pharma Inc. (OTCQB: BETRF) has filed an international PCT along with a U.S. patent application for the...

Mindset Pharma Inc. (OTCQB: MSSTF), a company producing psychedelic and non-psychedelic drugs for mental health conditions has recently identified three additional families of highly novel, non-tryptamine psychedelic compounds. Since its formation, Mindset has the goal of taking drug discovery...